SUBMISSION FORM University System/Employee Intellectual

ITEM 168-2020-R0915_A1
Submission Form
Page 1 of 4
SUBMISSION FORM
University System/Employee Intellectual Property Joint Participation
MUSP 407
This form is to be submitted with any Board of Regents item whereby a campus seeks the
approval of an agreement with or arrangement regarding an employee pursuant to 20-25-109
MCA and Regents Policy 407.
When the submission concerns matters of trade secrets or confidential business information, or
any other matter entitled to privacy under state or federal law (e.g., the federal statute known as
Bayh/Dole) the submitting campus may request consideration of the submission, in whole or in
part, in executive session.
The submitting campus should also provide the Commissioner a copy of the contract(s) that form
the basis for the cooperative arrangement for which approval is sought. Submission of the
contract does not indicate a conclusion that all or part of the contract is a public document and
the question of whether it is in whole or in part protected from public disclosure will be
evaluated on a case by case basis.
1. Summarize the nature of the intellectual property that was developed by the
employee seeking approval. Indicate the sources of funding for the research that
resulted in this invention.
The intellectual property is titled, “Cell based reporter assay to quantify the immunestimulatory properties of nutritional supplements” (Tech ID #JMA-2014-SUPP). Funding
was awarded by the National Institutes of Health. Psquare Scientific (“Psquare”) received
a Small Business Innovation Research (SBIR) award in April, 2015.
2.
a. Name(s) of the university employee(s) involved.
• Dr. Mark Jutila
o Lead Inventor of intellectual property
o Professor and Department Head, Microbiology &
Immunology, MSU
The MSU Office of Research Compliance is working with Dr. Jutila to develop a
Conflict of Interest Management Plan. The purpose of the plan is to accurately
describe the potential conflicts in writing, create explicit agreements to protect
against actual conflicts, and to facilitate oversight. A Plan Manager will be
assigned to review the case annually and whenever major changes in
circumstance occur. Once Dr. Jutila begins actively participating as an employee,
officer, board member, or equity holder, and he reaches the Significant Financial
Interest threshold, one of the safeguards of the Management Plan will include Dr.
Jutila’s agreement not to participate in any capacity on the MSU side on any
sponsored research or contracted work between MSU and Psquare, all pending
this BOR 407 approval.
ITEM 168-2020-R0915
Submission Form
Page 2 of 4
b. Name(s) of business entity(ies) involved.
Psquare Scientific, LLC, located in Damascus, Maryland. This company was
formed by a former MSU student and researcher, Dr. Jeffrey Holderness, who
worked in Dr. Jutila’s lab and is co-inventor on the MSU technology licensed to
Psquare. Dr. Holderness no longer works for MSU.
3. The university and employee(s) are seeking approval for (check as many as
appropriate):
a.
The employee to be awarded equity interest in the business entity
b.
The employee to serve as a member of the board of directors or other
governing board of the business entity
c.
The employee to accept employment from the business entity
d.
Other. Please explain.
4.
a. Summarize the nature of the relationship between the university and the
business entity (e.g., the entity is licensing the intellectual property from
the university, the entity is co-owning the intellectual property with the
university).
The intellectual property is owned by MSU, and the original Exclusive
License Agreement was executed September, 2014. This confidential
document is available upon request. The scope of the license gives Psquare an
exclusive, worldwide right to the intellectual property and patents with the
right to sublicense.
b. The proposed duration of the agreement or arrangement.
The License Agreement sets performance milestones annually, with sales set to
begin in 2017. No termination date is listed.
c. The conditions under which the agreement may be terminated or dissolved.
MSU may terminate this Agreement as follows:
1. If Psquare does not make a payment due and fails to cure such
nonpayment within forty-five days after the date of notice in writing of
such nonpayment by MSU.
2. If Psquare shall become insolvent, shall make an assignment for the
benefit of creditors, or shall have a petition in bankruptcy filed for or
against it. Such termination shall be effective immediately upon MSU
giving written notice to Psquare.
ITEM 168-2020-R0915
Submission Form
Page 3 of 4
3. If an examination by MSU's accountant shows an underreporting or
underpayment of Psquare in excess of twenty percent for any twelve
month period.
4. If Psquare fails to satisfy the performance milestones.
5. Without the obligation to provide notice, if Psquare files a claim,
including in any way the assertion that any portion of the patent rights
is invalid or unenforceable where the filing is by the Psquare, a third
party on behalf of the Psquare, or a third party at the written urging of
the Psquare.
All License Agreements (and possible future licenses as provided for by Option
Agreements) issued by the MSU Technology Transfer Office in which the
inventor seeks business participation are contingent upon this BOR 407 approval.
5. Explain specifically how the University System or the State of Montana will likely
benefit from the agreement or arrangement.
a. The IP owned by MSU under the negotiated license provides MSU with annual
maintenance and sublicensing fee income and royalties will generate revenue
upon successful commercial development of the technologies
b. Technical advances in the field with public and private contribution provides both
academic and economic development
c. Collaborative research opportunities for Montana State University and its students
6. Summarize the financial terms of the agreement or arrangement. Include:
a. The value, nature and source of the University’s contribution.
MSU will pay for patent costs and will be reimbursed by Psquare per the
upcoming license agreement. TTO will pursue patent prosecution and provide
marketing services and personnel hours. MSU will own any patents and retains
the right to use the technology and patents for academic research or other not-forprofit scholarly purposes.
b. The value and nature of the employee’s contribution.
As an MSU inventor, Dr. Jutila will assist in the preparation and completion of
the patent filings.
c. The anticipated revenue to be generated by the project and the time line
for generating such revenue.
The license agreement will set performance milestones for sales of the
licensed technology, as well as annually due sales and marketing reports.
There is no way to determine anticipated revenue at this early stage.
ITEM 168-2020-R0915
Submission Form
Page 4 of 4
d. The manner in which revenue and expenses will be shared by the parties.
Royalty revenues will be shared by MSU and the inventors after payment of a
development fee to MSU and collection of any unreimbursed patent costs. All
expense information will be detailed in the confidential agreement language.
e. The nature of each party’s equity interest in the project. If none, so indicate.
Dr. Jutila currently holds no equity in Psquare but plans to in the future.